Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Nivolumab Plus Relatlimab 360 mg/360 mg and Gemcitabine/Cisplatin as First-Line Treatment in Patients With Advanced Biliary Tract Cancer.(NOBLE）

NCT07369791 is registered in ClinicalTrials.gov with National Health Research Institutes, Taiwan as lead sponsor.

NCT NCT07369791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07369791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Nivolumab Plus Relatlimab 360 mg/360 mg and Gemcitabine/Cisplatin as First-Line Treatment in Patients With Advanced Biliary Tract Cancer.(NOBLE）
Lead sponsor
National Health Research Institutes, Taiwan
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2026
Completion date
December 31, 2040
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract cancer(btc)